Mark C. McKenna - Dec 9, 2022 Form 4 Insider Report for Prometheus Biosciences, Inc. (RXDX)

Role
Chairman, President & CEO, Director
Signature
/s/ Timothy K. Andrews, attorney-in-fact for Mark C. McKenna
Stock symbol
RXDX
Transactions as of
Dec 9, 2022
Transactions value $
$0
Form type
4
Date filed
12/13/2022, 07:32 PM
Previous filing
May 20, 2022
Next filing
Jan 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXDX Common Stock Award $0 +37.1K +205.83% $0.00 55.1K Dec 9, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXDX Stock Options (Right to Buy) Award $0 +129K $0.00 129K Dec 9, 2022 Common Stock 129K $110.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of restricted stock units ("RSUs") granted under the Issuer's 2021 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award will vest and settle with respect to twenty-five percent (25%) of the total number of RSUs on December 9, 2023, 2024, 2025 and 2026, subject to the Reporting Person's continued service with the Issuer through each vest date.
F2 Includes a total of 2,631 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
F3 25% of the shares subject to the option will vest on December 9, 2023, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.